BR9811184A - Vetor de adenovìrus porcino recombinante emétodo de produzir o mesmo - Google Patents

Vetor de adenovìrus porcino recombinante emétodo de produzir o mesmo

Info

Publication number
BR9811184A
BR9811184A BR9811184-1A BR9811184A BR9811184A BR 9811184 A BR9811184 A BR 9811184A BR 9811184 A BR9811184 A BR 9811184A BR 9811184 A BR9811184 A BR 9811184A
Authority
BR
Brazil
Prior art keywords
producing
recombinant
same
adenovirus vector
porcine adenovirus
Prior art date
Application number
BR9811184-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Michael Johnson
Jeffrey Michael Hammond
Original Assignee
Commw Scient Ind Res Org
Pig Res Dev Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3802849&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9811184(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Commw Scient Ind Res Org, Pig Res Dev Corp filed Critical Commw Scient Ind Res Org
Publication of BR9811184A publication Critical patent/BR9811184A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR9811184-1A 1997-08-14 1998-08-14 Vetor de adenovìrus porcino recombinante emétodo de produzir o mesmo BR9811184A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPO8560A AUPO856097A0 (en) 1997-08-14 1997-08-14 Vector
PCT/AU1998/000648 WO1999008706A1 (en) 1997-08-14 1998-08-14 Recombinant porcine adenovirus vector

Publications (1)

Publication Number Publication Date
BR9811184A true BR9811184A (pt) 2001-12-26

Family

ID=3802849

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9811184-1A BR9811184A (pt) 1997-08-14 1998-08-14 Vetor de adenovìrus porcino recombinante emétodo de produzir o mesmo

Country Status (17)

Country Link
US (3) US7323177B1 (enExample)
EP (2) EP1825863A1 (enExample)
JP (2) JP4365023B2 (enExample)
KR (1) KR100746524B1 (enExample)
CN (1) CN100366292C (enExample)
AT (1) ATE357250T1 (enExample)
AU (2) AUPO856097A0 (enExample)
BR (1) BR9811184A (enExample)
CY (1) CY1106565T1 (enExample)
DE (1) DE69837390T2 (enExample)
DK (1) DK1007088T3 (enExample)
ES (1) ES2283068T3 (enExample)
ID (1) ID24174A (enExample)
MX (1) MXPA00001562A (enExample)
NZ (1) NZ503039A (enExample)
PT (1) PT1007088E (enExample)
WO (1) WO1999008706A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO856097A0 (en) 1997-08-14 1997-09-04 Commonwealth Scientific And Industrial Research Organisation Vector
US6492343B1 (en) 1998-04-15 2002-12-10 University Of Saskatchewan Porcine adenovirus type 3 genome
FR2789695B1 (fr) * 1999-02-11 2003-03-07 Merial Sas Vecteurs et vaccins viraux a base d'adenovirus porcins recombines et replicatifs
FR2804028B1 (fr) * 2000-01-21 2004-06-04 Merial Sas Vaccins adn ameliores pour animaux de rente
WO2001083737A2 (en) * 2000-05-03 2001-11-08 University Of Guelph Porcine adenovirus type 5 vector and vaccine
WO2002031168A2 (en) * 2000-10-10 2002-04-18 Genstar Therapeutics Minimal adenoviral vector and recombinant vaccines based thereon
SK287969B6 (sk) 2001-03-27 2012-08-06 University Of Saskatchewan Method to culture circovirus
WO2003013598A2 (en) * 2001-08-09 2003-02-20 Lam Dominic M K Novel vaccine compositions and methods of vaccine preparation for veterinary and human diseases
EP1432791B2 (en) 2001-09-06 2013-10-23 Alphavax, Inc. Alphavirus replicon vector systems
JP3949520B2 (ja) * 2001-09-20 2007-07-25 独立行政法人科学技術振興機構 レギュカルチン過剰発現モデル動物
US7569217B2 (en) 2001-09-24 2009-08-04 University Of Saskatchewan Porcine adenovirus E1 and E4 regions
KR20030054139A (ko) * 2001-12-24 2003-07-02 학교법인 건국대학교 돼지 오제스키병 바이러스의 ｇＤ 유전자를 포함하는재조합 발현 벡터 및 이를 이용한 ＤＮＡ 백신
US7906311B2 (en) 2002-03-20 2011-03-15 Merial Limited Cotton rat lung cells for virus culture
EP1585812B1 (en) 2002-12-13 2017-01-18 Alphavax, Inc. Multi-antigenic alphavirus replicon particles and methods
EP2290054B1 (en) 2002-12-13 2017-03-29 Alphavax, Inc. Alphavirus particles and methods for preparation
JP5016305B2 (ja) 2003-03-20 2012-09-05 アルファヴァックス，インコーポレイテッド 改良されたアルファウイルスレプリコンおよびヘルパー構築物
ATE432285T1 (de) 2003-07-11 2009-06-15 Alphavax Inc Cytomegalovirusimpfstoffe, die auf dem alphavirus basieren
CA2567254C (en) 2004-05-18 2012-03-13 Alphavax, Inc. Tc-83-derived alphavirus vectors, particles and methods
RU2389506C2 (ru) * 2005-09-09 2010-05-20 Интервет Интернэшнл Б.В. Вакцина против рсv-2
CA2658805A1 (en) * 2006-07-28 2008-01-31 Commonwealth Scientific And Industrial Research Organisation Methods and compositions for increasing tissue tropism of recombinant adenoviral vectors
PL2947149T3 (pl) 2007-06-21 2018-09-28 Alphavax, Inc. Kasety bez promotora do ekspresji alfawirusowych białek strukturalnych
US20100150959A1 (en) * 2008-12-15 2010-06-17 Vectogen Pty Ltd. PCV 2-Based Methods and Compositions for the Treatment of Pigs
US20110135688A1 (en) * 2009-12-04 2011-06-09 Michael Sheppard Methods and Compositions for Increasing Titer of Recombinant Porcine Adenovirus-3 Vectors
CN105688201A (zh) * 2012-05-17 2016-06-22 佐蒂斯有限责任公司 在断奶之前对抗猪繁殖与呼吸综合征（prrs）病毒的有效疫苗接种
AU2015218769B2 (en) * 2014-02-20 2020-09-17 Vaxart, Inc. Formulations for small intestinal delivery
CA2988761A1 (en) 2015-06-12 2016-12-15 Vaxart, Inc. Formulations for small intestinal delivery of rsv and norovirus antigens
CA3047294A1 (en) 2016-12-14 2018-06-21 Zoetis Services Llc Effective vaccination against european strains of porcine reproductive and respiratory syndrome (prrs) virus prior to weaning
CN110904127B (zh) * 2018-09-18 2024-09-20 瓦赫宁恩研究基金会 非洲猪瘟病毒疫苗
CN116981697A (zh) 2021-01-14 2023-10-31 森迪生物科学公司 可分泌有效载荷调节

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4320068C1 (de) 1993-06-17 1994-12-15 Audi Ag Verfahren und Vorrichtung zur Reparatur von Fahrzeugkarosserien aus Leichtmetallteilen
BR9405507A (pt) 1993-07-13 1999-05-25 Rhone Poulenc Rorer Sa Adenovirus recombinante defeituoso linhagem celular e composição farmaceutica
EP0770157A4 (en) 1994-07-14 1998-01-07 Union Camp Patent Holding IMPROVED BLEACHING OF A VERY CONCENTRATED LIGNOCELLULOSIC PASTE
FR2725213B1 (fr) * 1994-10-04 1996-11-08 Rhone Poulenc Rorer Sa Vecteurs viraux et utilisation en therapie genique
ES2105984B1 (es) * 1995-11-30 1998-04-16 Iberica Cyanamid Adenovirus recombinantes que expresan antigenos del virus de la gastroenteritis porcina transmisible (vgpt) y su empleo en la formacion de vacunas.
AUPO856097A0 (en) * 1997-08-14 1997-09-04 Commonwealth Scientific And Industrial Research Organisation Vector
US6492343B1 (en) 1998-04-15 2002-12-10 University Of Saskatchewan Porcine adenovirus type 3 genome

Also Published As

Publication number Publication date
JP4365023B2 (ja) 2009-11-18
AU2011224111A1 (en) 2011-10-13
JP2009213495A (ja) 2009-09-24
CN1275084A (zh) 2000-11-29
HK1032755A1 (zh) 2001-08-03
EP1007088A4 (en) 2003-01-08
DK1007088T3 (da) 2007-06-04
ATE357250T1 (de) 2007-04-15
US7323177B1 (en) 2008-01-29
US20090226485A1 (en) 2009-09-10
WO1999008706A8 (en) 2000-08-10
AUPO856097A0 (en) 1997-09-04
EP1007088A1 (en) 2000-06-14
ID24174A (id) 2000-07-13
DE69837390T2 (de) 2007-08-23
US7785602B2 (en) 2010-08-31
PT1007088E (pt) 2007-05-31
EP1007088B1 (en) 2007-03-21
US20060263387A1 (en) 2006-11-23
NZ503039A (en) 2002-09-27
MXPA00001562A (es) 2004-10-14
WO1999008706A1 (en) 1999-02-25
KR100746524B1 (ko) 2007-08-07
CN100366292C (zh) 2008-02-06
US7473428B2 (en) 2009-01-06
DE69837390D1 (de) 2007-05-03
EP1825863A1 (en) 2007-08-29
ES2283068T3 (es) 2007-10-16
KR20010022882A (ko) 2001-03-26
JP2001514871A (ja) 2001-09-18
CY1106565T1 (el) 2012-01-25

Similar Documents

Publication Publication Date Title
BR9811184A (pt) Vetor de adenovìrus porcino recombinante emétodo de produzir o mesmo
DE69632235D1 (de) Newcastle-Krankheitsvirus-Kombinationsimpfstoff
HU0402350D0 (en) Recombinant mva-virus comprising a gene encoding a hiv net antigen ar an antigen determinant and use thereof
NO20001768L (no) Viruskapsomervaksine, fremgangsmÕte til fremstilling samt anvendelse derav
DE69529748D1 (de) Polynukleotide vakzine gegen den papilloma virus
MXPA02011545A (es) Virus del sindrome respiratorio y reproductor porcino (peesv), vacuna recombinante para el virus de la viruela.
NZ309659A (en) Composition comprising LbeIF4A and/or LmeIF4A polypeptides (Leishmania antigen) and methods for enhancing immune responses
AU7814498A (en) Multivalent (in ovo) avian vaccine
ATE352634T1 (de) Benutzung von immunmodulatoren zur herstellung von medikamenten zur inhibierung einer immunantwort gegen gleichzeitig verabreichte rekombinante viren
CA2057828A1 (en) Cytotoxic t lymphocyte-inducing lipopeptides and use as vaccines
EP1209226A3 (en) Maturation of dendritic cells by recombinant heat shock protein 70 (hsp70)
DK0889969T3 (da) Rekombinante adenovirale til genterapi af humane tumorer
BR9815285A (pt) Vetores alfavìrus para vacina de paramixovìrus
MXPA94008605A (es) Replicacion de un virus no patogenico que expresalas glicoproteinas de la envoltura del virus de ladiarrea viral bovina (bvdv).
WO1997003187A3 (en) Marek's disease virus genes and their use in vaccines for protection against marek's disease
AU657144B2 (en) Recombinant Marek's disease virus, process for preparing the same and vaccine containing the same
IL141443A0 (en) Vaccine comprising cytokine-induced heat shock proteins (hsp)
EP1155119A4 (en) VIRUS VACCINE CHARACTERIZED BY BHV-1 GENE DELETION
KR960702000A (ko) 귀밑샘염 바이러스로부터의 재조합 항원 및 백신에서의 이것의 사용방법(recombinant antigens from mumps virus and their use in vaccines)
FR2724385B1 (fr) Vaccin de la peritonite infectieuse feline.
ATE197609T1 (de) Verfahren zur unterdrückung der immunantwort durch gentherapie
ES2105984A1 (es) Adenovirus recombinantes que expresan antigenos del virus de la gastroenteritis porcina transmisible (vgpt) y su empleo en la formacion de vacunas.
Baxendale Marek's disease virus vaccine
MY157873A (en) Recombinant mva virus, and the use thereof

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ART. 37, INDEFIRO O PRESENTE PEDIDO, UMA VEZ QUE NAO ATENDE AO REQUISITO DE ATIVIDADE INVENTIVA ( ART. 8O COMBINADO COM O ART. 13 DA LPI 9279/96).

B12B Appeal against refusal [chapter 12.2 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 15A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2256 DE 01/04/2014.